Korro Bio Q2 EPS $(2.43) Misses $(2.40) Estimate
Portfolio Pulse from Benzinga Newsdesk
Korro Bio (NASDAQ:KRRO) reported a Q2 EPS of $(2.43), missing the analyst consensus estimate of $(2.40) by 1.25%. This represents a 96.19% improvement over the $(63.83) per share loss from the same period last year.
August 13, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Korro Bio reported a Q2 EPS of $(2.43), missing the analyst estimate of $(2.40) by 1.25%. Despite the miss, the loss is significantly lower than the $(63.83) per share loss from the same period last year.
The slight miss on EPS estimates is likely to have a negative short-term impact on the stock price. However, the significant improvement from last year's loss may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100